AU7322300A - Caspase inhibitor - Google Patents

Caspase inhibitor

Info

Publication number
AU7322300A
AU7322300A AU73223/00A AU7322300A AU7322300A AU 7322300 A AU7322300 A AU 7322300A AU 73223/00 A AU73223/00 A AU 73223/00A AU 7322300 A AU7322300 A AU 7322300A AU 7322300 A AU7322300 A AU 7322300A
Authority
AU
Australia
Prior art keywords
derivative
present
caspases
esters
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU73223/00A
Other languages
English (en)
Inventor
Hye-Kyung Chang
Hyun Ho Chung
Chang-Yuil Kang
Eunice Eun-Kyeong Kim
Young-Myeong Kim
Tae-Hee Lee
Changhee Min
Kwang-Yul Moon
Young-Leem Oh
Mi-Jeong Park
Tae-Kyo Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Corp
Original Assignee
LG Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/KR1999/000561 external-priority patent/WO2001021599A1/en
Priority claimed from KR10-1999-0048608A external-priority patent/KR100399361B1/ko
Application filed by LG Chemical Co Ltd filed Critical LG Chemical Co Ltd
Publication of AU7322300A publication Critical patent/AU7322300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AU73223/00A 1999-09-17 2000-09-18 Caspase inhibitor Abandoned AU7322300A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/KR1999/000561 WO2001021599A1 (en) 1999-09-17 1999-09-17 Caspase inhibitor
WOKR99/00561 1999-09-17
KR10-1999-0048608A KR100399361B1 (ko) 1999-11-04 1999-11-04 캐스파제 억제제 함유 치료제 조성물
KR9948608 1999-11-04
PCT/KR2000/001047 WO2001021600A1 (en) 1999-09-17 2000-09-18 Caspase inhibitor

Publications (1)

Publication Number Publication Date
AU7322300A true AU7322300A (en) 2001-04-24

Family

ID=26634563

Family Applications (1)

Application Number Title Priority Date Filing Date
AU73223/00A Abandoned AU7322300A (en) 1999-09-17 2000-09-18 Caspase inhibitor

Country Status (8)

Country Link
EP (1) EP1212309B1 (cg-RX-API-DMAC10.html)
JP (1) JP4195561B2 (cg-RX-API-DMAC10.html)
CN (1) CN1137888C (cg-RX-API-DMAC10.html)
AT (1) ATE273705T1 (cg-RX-API-DMAC10.html)
AU (1) AU7322300A (cg-RX-API-DMAC10.html)
CA (1) CA2388564C (cg-RX-API-DMAC10.html)
DE (1) DE60013147T2 (cg-RX-API-DMAC10.html)
WO (1) WO2001021600A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100399361B1 (ko) * 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
US7026111B2 (en) * 2001-10-15 2006-04-11 Beckman Coulter, Inc. Methods and reagents for improved cell-based assays
KR100594544B1 (ko) * 2003-08-27 2006-06-30 주식회사 엘지생명과학 이소옥사졸린 구조를 갖는 캐스파제 저해제
KR100774999B1 (ko) * 2005-02-26 2007-11-09 주식회사 엘지생명과학 이소옥사졸린 유도체 및 그의 제조 방법
EP1746167A1 (en) * 2005-07-20 2007-01-24 Apoxis SA Method for the identification of compounds susceptible to inhibit inflammation
WO2009013293A1 (en) * 2007-07-24 2009-01-29 Novartis Ag Substituted cyclohexanecarboxamides useful as bace inhibitors
KR20090099886A (ko) * 2008-03-18 2009-09-23 주식회사 엘지생명과학 캐스파제 저해제의 프로드럭
TW201919712A (zh) 2017-08-10 2019-06-01 法商塞勒尼斯醫療控股公司 運送子(cargomers)
TWI906428B (zh) * 2020-12-10 2025-12-01 南韓商Ｌｇ化學股份有限公司 酸（Ｂｏｒｏｎｉｃ Ａｃｉｄ）化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ283564B6 (cs) * 1993-11-26 1998-05-13 Pfizer Inc. 3-Aryl-2-isoxazolin-5-hydroxamové kyseliny a farmaceutické prostředky na jejich bázi
JP2818820B2 (ja) * 1993-11-26 1998-10-30 ファイザー・インク． 抗炎症剤としての３−アリール−２−イソオキサゾリン類
AU684887B2 (en) * 1994-03-09 1998-01-08 Pfizer Inc. Isoxazoline compounds as inhibitors of TNF release
BR9712987A (pt) * 1996-10-11 2000-04-18 Warner Lambert Co Inibidores de enzima de conversão de interleucina-1beta de sulfonamida
JPH11180891A (ja) * 1997-12-25 1999-07-06 Dai Ichi Seiyaku Co Ltd 抗細胞死剤
KR100373375B1 (ko) * 1998-04-03 2003-06-12 주식회사 엘지생명과학 인터루킨-1b-컨버팅효소및아포파인/cpp-32에대한저해제
WO2001021599A1 (en) * 1999-09-17 2001-03-29 Lg Chemical Ltd. Caspase inhibitor

Also Published As

Publication number Publication date
DE60013147D1 (en) 2004-09-23
JP2003509502A (ja) 2003-03-11
WO2001021600A1 (en) 2001-03-29
DE60013147T2 (de) 2005-08-11
EP1212309A1 (en) 2002-06-12
CN1137888C (zh) 2004-02-11
ATE273705T1 (de) 2004-09-15
EP1212309A4 (en) 2002-11-27
JP4195561B2 (ja) 2008-12-10
CN1377344A (zh) 2002-10-30
EP1212309B1 (en) 2004-08-18
CA2388564C (en) 2007-11-06
CA2388564A1 (en) 2001-03-29

Similar Documents

Publication Publication Date Title
CA2445145A1 (en) Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
EG20001A (en) Process for preparing of novel hydrox-amic acid and N-hydroxyurea derivatives and their use
IL111077A0 (en) Pharmacologically active pyridine derivatives and processes for the preparation thereof
UA84407C2 (en) Acetyl 2-hydroxy-1,3 diaminoalkanes
MXPA04006553A (es) Compuesto de 4-oxoquinolina y uso del mismo como inhibidor de integrasa de vih.
BG108806A (en) IIb/IIIa CELL ADHESION INHIIBITORS, METHOD FOR THE PRODUCTION, PHARMACEUTCIAL COMPOSITION AND ADMINISTRATION THEREOF
ATE407668T1 (de) Gamma-aminobuttersäurederivate enthaltende, feste arzneimittel und verfahren zu ihrer herstellung
MY127126A (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
UY25148A1 (es) Método para producir una composición farmacéutica que comprende un análogo de ácido gama aminobutírico (gaba) y una droga antiinflamatoria no esteroide (nsaid)
DE60140491D1 (de) Verwendung einer pharmazeutischen Zusammensetzung mit einem Para-Aminophenylessigsäurederivat für die Behandlung von entzündlichen Erkrankungen des Magen-Darmtrakts
DE60021873D1 (de) Zubereitung zur prophylaxe oder behandlung der demenz-erkrankung enthaltend ein hydroxyzimtsäurederivat oder einen extrakt einer pflanze der gattung angelica, der diese säure enthält.
EP1212309A4 (en) CASPASE INHIBITORS
MXPA02012889A (es) Esteres de acidos 4-alcoxi-ciclohexano-1-amino-carboxilicos y procedimiento para su obtencion.
TW200407133A (en) Novel PPARα and PPARγ agonists
NO20050667L (no) N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes
HUT67137A (en) Substituted mendelic acid derivatives. process for their production and pharmaceutical compositions comprising them
CA2362833A1 (en) Phenylalaninol derivatives
CA2202904A1 (en) Pharmaceutical composition for prophylaxis and treatment of type i allergic diseases
GR3032301T3 (en) N-hydroxyureas as antiinflammatory agents
WO2023239906A3 (en) Sialic acid derivatives and methods of using same
WO2004029019A8 (en) Compounds for the treatment of alzheimer’s disease
IT1273455B (it) Derivati tiolici ad attivita' inibitrice delle metallopeptidasi
UA85195C2 (ru) Амидометилзамещенные производные 1-(карбоксиалкил)-циклопентилкарбониламинобензазепин-n-уксусной кислоты, способ их получения, промежуточное соединение и фармацевтическая композиции на их основе
ES483463A1 (es) Procedimiento de preparacion de los esteres del 1-metil-4- piperidinol
YU89903A (sh) Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa i -gama aktivatori u lečenju dijabetesa

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase